Barr executive appointments
Barr promotes Paul Bisaro to the new position of president and COO of Barr Pharmaceuticals, the company announces on Jan. 10. Bisaro, who previously served as president and COO of Barr Laboratories, has already assumed the additional responsibilities. In addition, Frederick Wilkinson will join Barr in March as president and COO of Duramed Pharmaceuticals. Wilkinson, who most recently served as CEO and president of Columbia Laboratories, will report to Bisaro. Barr is likely to make further management changes in 2006; Duramed Research COO Carole Ben-Maimon in scheduled to resign in September (1"The Pink Sheet" Jan. 2, 2006, In Brief)...
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.